JP2006512094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512094A5 JP2006512094A5 JP2005510007A JP2005510007A JP2006512094A5 JP 2006512094 A5 JP2006512094 A5 JP 2006512094A5 JP 2005510007 A JP2005510007 A JP 2005510007A JP 2005510007 A JP2005510007 A JP 2005510007A JP 2006512094 A5 JP2006512094 A5 JP 2006512094A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sample
- acid sample
- less
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 544
- 108020004707 nucleic acids Proteins 0.000 claims description 463
- 102000039446 nucleic acids Human genes 0.000 claims description 463
- 238000000034 method Methods 0.000 claims description 277
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 178
- 230000003321 amplification Effects 0.000 claims description 177
- 125000003729 nucleotide group Chemical group 0.000 claims description 176
- 239000002773 nucleotide Substances 0.000 claims description 174
- 230000014509 gene expression Effects 0.000 claims description 156
- 230000010076 replication Effects 0.000 claims description 111
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 62
- 241000282414 Homo sapiens Species 0.000 claims description 50
- 238000006243 chemical reaction Methods 0.000 claims description 44
- 238000004458 analytical method Methods 0.000 claims description 36
- 238000006073 displacement reaction Methods 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 33
- 239000013592 cell lysate Substances 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 210000000349 chromosome Anatomy 0.000 claims description 28
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 24
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 24
- 238000010438 heat treatment Methods 0.000 claims description 24
- 238000011534 incubation Methods 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 238000004925 denaturation Methods 0.000 claims description 14
- 230000036425 denaturation Effects 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 5
- 230000003252 repetitive effect Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims 11
- 239000002336 ribonucleotide Substances 0.000 claims 11
- 230000000813 microbial effect Effects 0.000 claims 9
- 238000002360 preparation method Methods 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims 5
- 238000001574 biopsy Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 230000006037 cell lysis Effects 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 108020004418 ribosomal RNA Proteins 0.000 claims 3
- 230000000087 stabilizing effect Effects 0.000 claims 3
- 206010011409 Cross infection Diseases 0.000 claims 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 2
- 206010029803 Nosocomial infection Diseases 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 2
- 210000004381 amniotic fluid Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 210000004880 lymph fluid Anatomy 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000000582 semen Anatomy 0.000 claims 2
- 230000003584 silencer Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000005030 transcription termination Effects 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 238000000018 DNA microarray Methods 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 claims 1
- 108060002716 Exonuclease Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091092878 Microsatellite Proteins 0.000 claims 1
- 108091092919 Minisatellite Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims 1
- 210000004507 artificial chromosome Anatomy 0.000 claims 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 102000013165 exonuclease Human genes 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000005382 thermal cycling Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 294
- 239000013615 primer Substances 0.000 description 181
- 239000000523 sample Substances 0.000 description 121
- 108700028369 Alleles Proteins 0.000 description 27
- 238000003753 real-time PCR Methods 0.000 description 19
- 230000008439 repair process Effects 0.000 description 19
- 210000002593 Y chromosome Anatomy 0.000 description 18
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 16
- 102100023132 Transcription factor Jun Human genes 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000013412 genome amplification Methods 0.000 description 12
- 230000004544 DNA amplification Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 238000003505 heat denaturation Methods 0.000 description 9
- 101150084750 1 gene Proteins 0.000 description 8
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 108010014510 connexin 40 Proteins 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108091023043 Alu Element Proteins 0.000 description 3
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 3
- 102000002278 Ribosomal Proteins Human genes 0.000 description 3
- 108010000605 Ribosomal Proteins Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 101150117962 DUSP1 gene Proteins 0.000 description 2
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101150012093 MKP1 gene Proteins 0.000 description 2
- 101100478343 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srk1 gene Proteins 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- 101150066838 12 gene Proteins 0.000 description 1
- 101150025032 13 gene Proteins 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- 101150076401 16 gene Proteins 0.000 description 1
- 101150016096 17 gene Proteins 0.000 description 1
- 101150078635 18 gene Proteins 0.000 description 1
- 101150040471 19 gene Proteins 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
Images
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/327,602 US9487823B2 (en) | 2002-12-20 | 2002-12-20 | Nucleic acid amplification |
| US10/327,602 | 2002-12-20 | ||
| US10/429,229 US7297485B2 (en) | 2001-10-15 | 2003-05-02 | Method for nucleic acid amplification that results in low amplification bias |
| US10/429,229 | 2003-05-02 | ||
| US10/456,056 US7955795B2 (en) | 2003-06-06 | 2003-06-06 | Method of whole genome amplification with reduced artifact production |
| US10/456,056 | 2003-06-06 | ||
| PCT/US2003/040364 WO2004058987A2 (en) | 2002-12-20 | 2003-12-19 | Nucleic acid amplification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010042086A Division JP2010158250A (ja) | 2002-12-20 | 2010-02-26 | 核酸増幅 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006512094A JP2006512094A (ja) | 2006-04-13 |
| JP2006512094A5 true JP2006512094A5 (enExample) | 2010-09-09 |
| JP4886298B2 JP4886298B2 (ja) | 2012-02-29 |
Family
ID=32685977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005510007A Expired - Lifetime JP4886298B2 (ja) | 2002-12-20 | 2003-12-19 | 核酸増幅 |
| JP2010042086A Pending JP2010158250A (ja) | 2002-12-20 | 2010-02-26 | 核酸増幅 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010042086A Pending JP2010158250A (ja) | 2002-12-20 | 2010-02-26 | 核酸増幅 |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP1583843B1 (enExample) |
| JP (2) | JP4886298B2 (enExample) |
| AU (1) | AU2003299694A1 (enExample) |
| CA (1) | CA2510587A1 (enExample) |
| WO (1) | WO2004058987A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977162B2 (en) | 2002-03-01 | 2005-12-20 | Ravgen, Inc. | Rapid analysis of variations in a genome |
| US20070178478A1 (en) * | 2002-05-08 | 2007-08-02 | Dhallan Ravinder S | Methods for detection of genetic disorders |
| US7727720B2 (en) | 2002-05-08 | 2010-06-01 | Ravgen, Inc. | Methods for detection of genetic disorders |
| US7442506B2 (en) | 2002-05-08 | 2008-10-28 | Ravgen, Inc. | Methods for detection of genetic disorders |
| US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
| US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
| JP4793842B2 (ja) * | 2004-11-24 | 2011-10-12 | 独立行政法人農業生物資源研究所 | ランダムｒｎａプライマーを用いたｄｎａの増幅方法 |
| JP2006262777A (ja) * | 2005-03-24 | 2006-10-05 | Japan Science & Technology Agency | 夾雑物を含む試料を用いた核酸合成方法及び添加剤 |
| US9139849B2 (en) | 2005-04-08 | 2015-09-22 | The United States of America as Represented by the Government of the Department of Health and Human Services | Rapid generation of long synthetic centromeric tandem repeats for mammalian artificial chromosome formation |
| WO2007052101A1 (en) * | 2005-04-15 | 2007-05-10 | Genomictree, Inc. | Linear amplification of rna using a high-heel primer |
| EP1762627A1 (de) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion |
| US8921086B2 (en) | 2005-12-22 | 2014-12-30 | Pacific Biosciences Of California, Inc. | Polymerases for nucleotide analogue incorporation |
| US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
| WO2008143627A2 (en) * | 2006-09-14 | 2008-11-27 | Ibis Biosciences, Inc. | Targeted whole genome amplification method for identification of pathogens |
| US20080096258A1 (en) * | 2006-10-24 | 2008-04-24 | Christian Korfhage | Rolling circle amplification of circular genomes |
| DE102007010311A1 (de) * | 2007-02-23 | 2008-08-28 | Thines, Marco, Dr. | Organismusspezifisches hybridisierbares Nucleinsäuremolekül |
| FR2940805B1 (fr) * | 2009-01-05 | 2015-10-16 | Biomerieux Sa | Procede d'amplification et/ou de detection d'acides nucleiques, kits et utilisations de ce procede |
| KR101378214B1 (ko) | 2009-06-29 | 2014-03-27 | 가부시끼가이샤 도시바 | 검체 해석 방법 및 그것에 사용하는 분석 키트 |
| JP4528889B1 (ja) * | 2010-02-22 | 2010-08-25 | 株式会社東芝 | 検体解析方法およびそこにおいて使用されるアッセイキット |
| CN102533960B (zh) * | 2010-12-31 | 2014-04-30 | 深圳华大基因科技有限公司 | 一种单细胞基因组分析方法及试剂盒 |
| JP5688702B2 (ja) * | 2011-03-14 | 2015-03-25 | 国立大学法人北海道大学 | 核酸増幅方法およびその利用 |
| PL2831279T3 (pl) * | 2012-03-26 | 2023-12-04 | The Johns Hopkins University | Szybkie wykrywanie aneuploidii |
| EP2877593B1 (en) | 2012-07-26 | 2018-07-18 | Illumina, Inc. | Compositions and methods for the amplification of nucleic acids |
| KR101935367B1 (ko) * | 2012-07-26 | 2019-01-04 | 삼성전자주식회사 | 이온성 액체를 사용하여 생물학적 시료로부터 핵산 증폭의 증폭 효율 및 감도를 증가시키는 방법 |
| DK2935617T3 (en) * | 2012-12-21 | 2017-07-17 | Samplix S A R L | Likelihood-oriented isolation of nucleotide sequences (PINS) |
| US9938568B2 (en) | 2013-07-26 | 2018-04-10 | General Electric Company | Ligase-assisted nucleic acid circularization and amplification |
| US9587263B2 (en) | 2014-03-26 | 2017-03-07 | General Electric Company | Isothermal amplification under low salt condition |
| EP4151751A1 (en) | 2016-04-14 | 2023-03-22 | T2 Biosystems, Inc. | Methods and systems for amplification in complex samples |
| CN108179198B (zh) * | 2018-01-24 | 2020-02-07 | 扬州大学 | 一种基于line1转座子与微卫星引物相结合的猪基因组分子标记的挖掘方法 |
| US11720801B2 (en) | 2020-08-25 | 2023-08-08 | International Business Machines Corporation | Chemical reaction network for estimating concentration of chemical species based on an identified pattern of output chemical species |
| WO2023133094A1 (en) * | 2022-01-04 | 2023-07-13 | Enumerix, Inc. | Accurate sequencing library generation via ultra-high partitioning |
| CN116083550B (zh) * | 2022-07-20 | 2024-10-11 | 四川大学 | 一种短串联重复序列的检测方法、引物组、试剂盒和应用 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| CA1190838A (en) | 1981-07-17 | 1985-07-23 | Cavit Akin | Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| JP2828642B2 (ja) | 1987-06-24 | 1998-11-25 | ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン | ヌクレオシド誘導体 |
| US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
| US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
| WO1989009221A1 (en) | 1988-03-25 | 1989-10-05 | University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5198543A (en) | 1989-03-24 | 1993-03-30 | Consejo Superior Investigaciones Cientificas | PHI29 DNA polymerase |
| US5001050A (en) | 1989-03-24 | 1991-03-19 | Consejo Superior Investigaciones Cientificas | PHφ29 DNA polymerase |
| US5043272A (en) | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| DK0455905T3 (da) | 1990-05-11 | 1998-12-07 | Microprobe Corp | Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider |
| US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| JPH0874B2 (ja) | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| PT98562B (pt) | 1990-08-03 | 1999-01-29 | Sanofi Sa | Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases |
| US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
| US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
| JPH06505704A (ja) | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ，インコーポレイテッド | 改変ヌクレオシド間結合 |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5455166A (en) * | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
| EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| ES2107205T3 (es) | 1993-03-30 | 1997-11-16 | Sanofi Sa | Analogos de nucleosidos aciclicos y secuencias oligonucleotidas que los contienen. |
| HU9501974D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthrop Inc | Oligonucleotides with amide linkages replacing phosphodiester linkages |
| DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
| US6294664B1 (en) | 1993-07-29 | 2001-09-25 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| CA2185239C (en) | 1994-03-16 | 2002-12-17 | Nanibhushan Dattagupta | Isothermal strand displacement nucleic acid amplification |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
| ATE280243T1 (de) | 1994-04-29 | 2004-11-15 | Johnson & Johnson Clin Diag | Homogenes verfahren zum nachweis von doppelstrang-nukleinsäuren mittels fluoreszierender farbstoffe und dafür nützliche kits |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US6479235B1 (en) * | 1994-09-30 | 2002-11-12 | Promega Corporation | Multiplex amplification of short tandem repeat loci |
| US5451067A (en) | 1994-10-18 | 1995-09-19 | Pieper; Julius A. | Chuck key with integral holder |
| AT402203B (de) * | 1995-06-13 | 1997-03-25 | Himmler Gottfried Dipl Ing Dr | Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren |
| US5658735A (en) | 1995-11-09 | 1997-08-19 | Biometric Imaging, Inc. | Cyclized fluorescent nucleic acid intercalating cyanine dyes and nucleic acid detection methods |
| US5734058A (en) | 1995-11-09 | 1998-03-31 | Biometric Imaging, Inc. | Fluorescent DNA-Intercalating cyanine dyes including a positively charged benzothiazole substituent |
| ATE199572T1 (de) | 1995-11-21 | 2001-03-15 | Univ Yale | Unimolekulare segmentamplifikation und bestimmung |
| US6458556B1 (en) * | 1996-07-25 | 2002-10-01 | The Institute Of Physical & Chemical Research | Method for enhancing enzyme activity at elevated temperature |
| SE9603171D0 (sv) | 1996-08-30 | 1996-08-30 | Marek Kwiatkowski | Solid phase synthesis |
| WO1998030721A1 (en) | 1997-01-10 | 1998-07-16 | Pioneer Hi-Bred International, Inc. | Hybridization-based genetic amplification and analysis |
| US6297006B1 (en) | 1997-01-16 | 2001-10-02 | Hyseq, Inc. | Methods for sequencing repetitive sequences and for determining the order of sequence subfragments |
| US6124120A (en) * | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
| US6087102A (en) | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
| US6287776B1 (en) | 1998-02-02 | 2001-09-11 | Signature Bioscience, Inc. | Method for detecting and classifying nucleic acid hybridization |
| JP3944996B2 (ja) | 1998-03-05 | 2007-07-18 | 株式会社日立製作所 | Ｄｎａプローブアレー |
| US6312902B1 (en) | 1998-03-13 | 2001-11-06 | Promega Corporation | Nucleic acid detection |
| US6031078A (en) | 1998-06-16 | 2000-02-29 | Millennium Pharmaceuticals, Inc. | MTbx protein and nucleic acid molecules and uses therefor |
| US6180408B1 (en) | 1998-08-21 | 2001-01-30 | Washington University | Fluorescence polarization in nucleic acid analysis |
| CA2342837A1 (en) * | 1998-09-15 | 2000-03-23 | Yale University | Artificial long terminal repeat vectors |
| IL149676A0 (en) | 1999-12-02 | 2002-11-10 | Dna Sciences Inc | Methods and kits for determining nucleotide variations |
| US6323009B1 (en) * | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
| US6479244B1 (en) | 2001-04-23 | 2002-11-12 | Galileo Genomics | Method for genotyping microsatellite DNA markers |
| US6679242B1 (en) | 2003-01-07 | 2004-01-20 | Martin Archery, Inc. | Archery bowstring accessory and method of increasing arrow speed and reducing bowstring vibration in shooting an arrow from an archery bow |
-
2003
- 2003-12-19 JP JP2005510007A patent/JP4886298B2/ja not_active Expired - Lifetime
- 2003-12-19 WO PCT/US2003/040364 patent/WO2004058987A2/en not_active Ceased
- 2003-12-19 AU AU2003299694A patent/AU2003299694A1/en not_active Abandoned
- 2003-12-19 CA CA002510587A patent/CA2510587A1/en not_active Abandoned
- 2003-12-19 EP EP03799976.0A patent/EP1583843B1/en not_active Expired - Lifetime
- 2003-12-19 EP EP10178502.0A patent/EP2261371B1/en not_active Expired - Lifetime
-
2010
- 2010-02-26 JP JP2010042086A patent/JP2010158250A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006512094A5 (enExample) | ||
| EP2379753B1 (en) | Single-cell nucleic acid analysis | |
| JP4886298B2 (ja) | 核酸増幅 | |
| US8673567B2 (en) | Method and kit for nucleic acid sequence detection | |
| EP2310522B1 (en) | Real time polymerase chain reaction process using a universal detection system | |
| US20100184152A1 (en) | Target-oriented whole genome amplification of nucleic acids | |
| US20090099041A1 (en) | Methods for making nucleotide probes for sequencing and synthesis | |
| EP2872650A2 (en) | Human identifiation using a panel of snps | |
| JPWO2010001969A1 (ja) | 標的核酸配列の増幅方法、それを用いた変異の検出方法、および、それに用いる試薬 | |
| CN112980933B (zh) | 一种基于CRISPR-Cas体系的SNP分型检测方法及其应用 | |
| US20140295419A1 (en) | Methods and compositions for isothermal whole genome amplification | |
| JP4249186B2 (ja) | 核酸の増幅方法 | |
| Sensabaugh et al. | The polymerase chain reaction: application to the analysis of biological evidence | |
| KR101312480B1 (ko) | 돼지의 갈비뼈 수 판단용 ｓｎｐ 마커 및 이의 용도 | |
| KR20200024167A (ko) | Rna 및 dna로부터의 핵산 라이브러리의 제조 | |
| KR102237248B1 (ko) | 소나무 개체식별 및 집단의 유전 분석용 snp 마커 세트 및 이의 용도 | |
| US20230374574A1 (en) | Compositions and methods for highly sensitive detection of target sequences in multiplex reactions | |
| JP4601830B2 (ja) | カップル性ポリメラーゼ連鎖反応−制限エンドヌクレアーゼ消化−リガーゼ検出反応法 | |
| WO2019023243A1 (en) | METHODS AND COMPOSITIONS FOR SELECTING AND AMPLIFYING DNA TARGETS IN A SINGLE REACTION MIXTURE | |
| KR102083675B1 (ko) | 단일염기다형성 마커를 이용한 칡소 품종 식별 방법 | |
| WO2022126750A1 (zh) | 一种检测受体样品中供体的存在或比例的方法和试剂盒 | |
| KR102797096B1 (ko) | 백색돼지 품종에서 유색인자 판별용 snp 마커 및 이의 용도 | |
| KR20230173442A (ko) | 백색돼지 품종에서 유색인자 판별용 snp 마커 및 이의 용도 | |
| WO2023107682A1 (en) | Methods for the detection of a nucleic acid | |
| KR101823376B1 (ko) | 돈육내 스테아릭산 함량 조절용 snp 마커 및 그의 용도 |